EWTX logo

Edgewise Therapeutics, Inc. (EWTX) Cash From Operations

Annual CFO:

-$109.03M-$17.08M(-18.58%)
December 31, 2024

Summary

  • As of today, EWTX annual cash from operations is -$109.03 million, with the most recent change of -$17.08 million (-18.58%) on December 31, 2024.
  • During the last 3 years, EWTX annual cash from operations has fallen by -$75.52 million (-225.39%).
  • EWTX annual cash from operations is now -1088.83% below its all-time high of -$9.17 million, reached on December 31, 2019.

Performance

EWTX Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherEWTXcash flow metrics

Quarterly CFO:

-$34.78M-$2.19M(-6.73%)
September 30, 2025

Summary

  • As of today, EWTX quarterly cash from operations is -$34.78 million, with the most recent change of -$2.19 million (-6.73%) on September 30, 2025.
  • Over the past year, EWTX quarterly cash from operations has dropped by -$7.40 million (-27.04%).
  • EWTX quarterly cash from operations is now -1169.66% below its all-time high of -$2.74 million, reached on March 31, 2020.

Performance

EWTX Quarterly Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherEWTXcash flow metrics

TTM CFO:

-$132.18M-$7.40M(-5.93%)
September 30, 2025

Summary

  • As of today, EWTX TTM cash from operations is -$132.18 million, with the most recent change of -$7.40 million (-5.93%) on September 30, 2025.
  • Over the past year, EWTX TTM cash from operations has dropped by -$23.28 million (-21.38%).
  • EWTX TTM cash from operations is now -4725.89% below its all-time high of -$2.74 million, reached on March 31, 2020.

Performance

EWTX TTM Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherEWTXcash flow metrics

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

EWTX Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-18.6%-27.0%-21.4%
3Y3 Years-225.4%-189.8%-163.1%
5Y5 Years-1088.8%--

EWTX Cash From Operations Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-225.4%at low-194.2%+8.2%-163.1%at low
5Y5-Year-1088.8%at low-772.7%+8.2%-1865.8%at low
All-TimeAll-Time-1088.8%at low-1169.7%+8.2%-4725.9%at low

EWTX Cash From Operations History

DateAnnualQuarterlyTTM
Sep 2025
-
-$34.78M(-6.7%)
-$132.18M(-5.9%)
Jun 2025
-
-$32.58M(+14.0%)
-$124.78M(-5.5%)
Mar 2025
-
-$37.87M(-40.5%)
-$118.30M(-8.5%)
Dec 2024
-$109.03M(-18.6%)
-$26.96M(+1.5%)
-$109.03M(-0.1%)
Sep 2024
-
-$27.37M(-4.9%)
-$108.90M(-5.1%)
Jun 2024
-
-$26.10M(+8.7%)
-$103.58M(-6.0%)
Mar 2024
-
-$28.60M(-6.6%)
-$97.72M(-6.3%)
Dec 2023
-$91.95M(-74.7%)
-$26.83M(-21.6%)
-$91.95M(-19.5%)
Sep 2023
-
-$22.06M(-9.0%)
-$76.94M(-15.0%)
Jun 2023
-
-$20.23M(+11.4%)
-$66.88M(-6.3%)
Mar 2023
-
-$22.83M(-93.1%)
-$62.89M(-19.5%)
DateAnnualQuarterlyTTM
Dec 2022
-$52.63M(-57.1%)
-$11.82M(+1.5%)
-$52.63M(-4.8%)
Sep 2022
-
-$12.00M(+26.1%)
-$50.23M(-8.0%)
Jun 2022
-
-$16.25M(-29.2%)
-$46.50M(-16.2%)
Mar 2022
-
-$12.57M(-33.5%)
-$40.02M(-19.4%)
Dec 2021
-$33.51M(-129.0%)
-$9.42M(-14.0%)
-$33.51M(-39.1%)
Sep 2021
-
-$8.26M(+15.4%)
-$24.09M(-52.2%)
Jun 2021
-
-$9.77M(-61.3%)
-$15.83M(-57.6%)
Mar 2021
-
-$6.06M(-52.0%)
-$10.04M(-49.3%)
Dec 2020
-$14.63M(-59.6%)
-
-
Jun 2020
-
-$3.98M(-45.5%)
-$6.72M(-145.5%)
Mar 2020
-
-$2.74M
-$2.74M
Dec 2019
-$9.17M
-
-

FAQ

  • What is Edgewise Therapeutics, Inc. annual cash from operations?
  • What is the all-time high annual cash from operations for Edgewise Therapeutics, Inc.?
  • What is Edgewise Therapeutics, Inc. annual cash from operations year-on-year change?
  • What is Edgewise Therapeutics, Inc. quarterly cash from operations?
  • What is the all-time high quarterly cash from operations for Edgewise Therapeutics, Inc.?
  • What is Edgewise Therapeutics, Inc. quarterly cash from operations year-on-year change?
  • What is Edgewise Therapeutics, Inc. TTM cash from operations?
  • What is the all-time high TTM cash from operations for Edgewise Therapeutics, Inc.?
  • What is Edgewise Therapeutics, Inc. TTM cash from operations year-on-year change?

What is Edgewise Therapeutics, Inc. annual cash from operations?

The current annual cash from operations of EWTX is -$109.03M

What is the all-time high annual cash from operations for Edgewise Therapeutics, Inc.?

Edgewise Therapeutics, Inc. all-time high annual cash from operations is -$9.17M

What is Edgewise Therapeutics, Inc. annual cash from operations year-on-year change?

Over the past year, EWTX annual cash from operations has changed by -$17.08M (-18.58%)

What is Edgewise Therapeutics, Inc. quarterly cash from operations?

The current quarterly cash from operations of EWTX is -$34.78M

What is the all-time high quarterly cash from operations for Edgewise Therapeutics, Inc.?

Edgewise Therapeutics, Inc. all-time high quarterly cash from operations is -$2.74M

What is Edgewise Therapeutics, Inc. quarterly cash from operations year-on-year change?

Over the past year, EWTX quarterly cash from operations has changed by -$7.40M (-27.04%)

What is Edgewise Therapeutics, Inc. TTM cash from operations?

The current TTM cash from operations of EWTX is -$132.18M

What is the all-time high TTM cash from operations for Edgewise Therapeutics, Inc.?

Edgewise Therapeutics, Inc. all-time high TTM cash from operations is -$2.74M

What is Edgewise Therapeutics, Inc. TTM cash from operations year-on-year change?

Over the past year, EWTX TTM cash from operations has changed by -$23.28M (-21.38%)
On this page